Contact
Please use this form to send email to PR contact of this press release:
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
TO:
Please use this form to send email to PR contact of this press release:
Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
TO: